ADC Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ADC Therapeutics SA
ADCT Stock  USD 3.53  0.03  0.86%   
Analyzing historical trends in various income statement and balance sheet accounts from ADC Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ADC Therapeutics' valuation are summarized below:
Gross Profit
-43.2 M
Profit Margin
(2.22)
Market Capitalization
437.3 M
Enterprise Value Revenue
4.2523
Revenue
75.2 M
There are currently one hundred twenty fundamental measures for ADC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should validate ADC Therapeutics' latest fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 211.2 M in 2026. Enterprise Value is likely to drop to about 71.5 M in 2026

ADC Therapeutics Total Revenue

53.56 Million

Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 156.9 K, Interest Income of 14.8 M or Depreciation And Amortization of 2 M, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0 or Days Sales Outstanding of 114. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with ADC Stock
Check out the analysis of ADC Therapeutics Correlation against competitors.

ADC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets368.4 M370.3 M275.5 M
Slightly volatile
Other Current Liabilities36.5 M70.2 M25.8 M
Slightly volatile
Total Current Liabilities51 M92.5 M36.4 M
Slightly volatile
Property Plant And Equipment Net8 M15.4 M5.5 M
Slightly volatile
Current Deferred Revenue4.5 M4.3 M2.5 M
Slightly volatile
Accounts Payable21.8 M20.7 M8.1 M
Slightly volatile
Cash296.1 M288.5 M227.6 M
Slightly volatile
Non Current Assets Total15.9 M16.8 M19.7 M
Slightly volatile
Cash And Short Term Investments296.1 M288.5 M227.6 M
Slightly volatile
Net Receivables20.1 M23.4 M14.3 M
Slightly volatile
Liabilities And Stockholders Equity368.4 M370.3 M275.5 M
Slightly volatile
Non Current Liabilities Total536.3 M510.8 M165.5 M
Slightly volatile
Other Current Assets10.9 M20.5 M7.7 M
Slightly volatile
Other Stockholder Equity892.4 M1.5 B658.9 M
Slightly volatile
Total Liabilities633.5 M603.3 M204.6 M
Slightly volatile
Total Current Assets334.3 M353.5 M254.7 M
Slightly volatile
Intangible Assets9.7 M16.5 M7.9 M
Slightly volatile
Common Stock5 M9.7 M3.4 M
Slightly volatile
Other Liabilities36.3 M29.1 M19.4 M
Slightly volatile
Net Tangible Assets64.4 M67.8 M177 M
Slightly volatile
Other Assets1.091.153.5 M
Pretty Stable
Common Stock Total Equity7.6 M7.3 M3.2 M
Slightly volatile
Common Stock Shares Outstanding79.6 M111.7 M69.5 M
Slightly volatile
Capital Surpluse361.8 M407 M444.3 M
Slightly volatile
Inventory22.2 M21.1 M6.7 M
Slightly volatile
Property Plant And Equipment Gross11 M21.6 M7.1 M
Slightly volatile
Net Working Capital298.5 M261 M261.3 M
Pretty Stable
Property Plant Equipment6.4 M11.5 M4.8 M
Slightly volatile
Capital Stock6.4 M9.7 M3.5 M
Slightly volatile
Short and Long Term Debt Total116.8 M141.4 M55.3 M
Slightly volatile
Capital Lease Obligations8.3 M10.8 M6.4 M
Slightly volatile
Short Term Debt1.2 M1.2 M2.5 M
Slightly volatile
Long Term Debt89.1 M102.3 M107.5 M
Pretty Stable
Short and Long Term Debt8.3 M14.3 M6.3 M
Slightly volatile
Non Current Liabilities Other3.4 M2.8 M1.3 M
Slightly volatile
Deferred Long Term Liabilities871.8 K1.1 M729.6 K
Slightly volatile

ADC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income14.8 M14.1 M4.7 M
Slightly volatile
Depreciation And Amortization2 M3.8 M1.4 M
Slightly volatile
Interest Expense60.6 M57.7 M17.6 M
Slightly volatile
Selling General Administrative55.3 M74.1 M34.5 M
Slightly volatile
Other Operating Expenses223.8 M231.7 M161 M
Slightly volatile
Research Development142.3 M126.1 M111.9 M
Slightly volatile
Cost Of Revenue5.1 M5.4 M63.3 M
Slightly volatile
Total Operating Expenses202.5 M224.9 M150.2 M
Slightly volatile
Reconciled Depreciation2.2 M3.8 M1.4 M
Slightly volatile
Selling And Marketing Expenses28.3 M19.3 M26.2 M
Slightly volatile

ADC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.2 M7.6 M11.3 M
Slightly volatile
Begin Period Cash Flow298.6 M320.4 M223.3 M
Slightly volatile
Depreciation2.7 M3.8 M1.7 M
Slightly volatile
Capital Expenditures741.3 K780.3 K2.7 M
Slightly volatile
End Period Cash Flow313.3 M288.5 M277.6 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.983.14594
Slightly volatile
Days Sales Outstanding114120293
Slightly volatile
Stock Based Compensation To Revenue0.10.110.5609
Pretty Stable
Capex To Depreciation0.290.35.0128
Slightly volatile
Inventory Turnover0.350.37143
Slightly volatile
Days Of Inventory On Hand9771 K691
Slightly volatile
Payables Turnover0.360.388.3351
Slightly volatile
Sales General And Administrative To Revenue0.991.053.3211
Slightly volatile
Research And Ddevelopement To Revenue1.691.7832.1352
Slightly volatile
Capex To Revenue0.01340.01411.033
Slightly volatile
Cash Per Share4.372.974.1367
Pretty Stable
Days Payables Outstanding854996625
Slightly volatile
Income Quality0.920.90.8458
Very volatile
Intangibles To Total Assets0.02460.02630.0257
Slightly volatile
Net Debt To EBITDA1.741.422.1141
Slightly volatile
Current Ratio4.174.3910.3426
Slightly volatile
Receivables Turnover1.713.141.6152
Slightly volatile
Capex Per Share0.00970.01030.043
Slightly volatile
Revenue Per Share0.540.660.3913
Slightly volatile
Interest Debt Per Share1.11.60.6823
Slightly volatile
Debt To Assets0.360.340.1343
Slightly volatile
Operating Cycle1 K1.1 K887
Slightly volatile
Days Of Payables Outstanding854996625
Slightly volatile
Ebt Per Ebit0.861.081.0253
Slightly volatile
Quick Ratio3.924.1310.2541
Slightly volatile
Net Income Per E B T0.820.910.9943
Pretty Stable
Cash Ratio3.413.599.659
Slightly volatile
Cash Conversion Cycle229146268
Slightly volatile
Days Of Inventory Outstanding9771 K691
Slightly volatile
Days Of Sales Outstanding114120293
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0441
Slightly volatile
Fixed Asset Turnover4.094.753.4511
Slightly volatile
Debt Ratio0.360.340.1343
Slightly volatile
Price Sales Ratio2.983.14594
Slightly volatile
Asset Turnover0.10.20.0783
Slightly volatile

ADC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap211.2 M222.4 M1.3 B
Slightly volatile

ADC Fundamental Market Drivers

ADC Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ADC Therapeutics Financial Statements

ADC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.3 M4.5 M
Total Revenue81.5 M53.6 M
Cost Of Revenue5.4 M5.1 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 1.05  0.99 
Research And Ddevelopement To Revenue 1.78  1.69 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.66  0.54 
Ebit Per Revenue(1.66)(1.74)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY